Core Viewpoint - The stock price of Koyuan Pharmaceutical (301281) plummeted after the announcement that its second-largest shareholder, Wen Zehong, plans to reduce his stake by 3%, indicating potential lack of confidence in the company's future performance [1][6]. Group 1: Stock Performance - On May 26, Koyuan Pharmaceutical's stock fell by 8.03%, closing at 32.42 yuan per share, with a total market capitalization of 3.511 billion yuan [3]. - The stock opened down 5.39% and experienced a decline of over 10% during the trading session [3]. - The trading volume for the day was 317 million yuan, with a turnover rate of 14.34% [3]. Group 2: Shareholder Actions - Wen Zehong, the second-largest shareholder, holds 8.4 million shares, representing 7.76% of the total share capital [4]. - The planned reduction involves selling up to 3.2487 million shares, which is 3% of the total share capital, through both centralized bidding and block trading [3][5]. Group 3: Financial Performance - Koyuan Pharmaceutical's revenue for 2023 was approximately 448 million yuan, a year-on-year increase of 1.07%, but the net profit attributable to shareholders decreased by 15.6% to about 77 million yuan [9]. - In 2024, the company expects a further decline in net profit, projected at 60.4 million yuan, down 21.54% year-on-year, despite a revenue increase to approximately 464 million yuan [9]. - The company attributed the profit decline to increased sales costs, lower sales prices, and higher asset impairment losses [9]. Group 4: Future Plans - Koyuan Pharmaceutical is planning a restructuring, aiming to acquire 99.42% of Hongjitang's shares for approximately 3.581 billion yuan and raise up to 700 million yuan through a share issuance to specific investors [10]. - The restructuring aims to expand the company's business into traditional Chinese medicine and health products [10].
第二大股东减持计划吓崩股价，科源制药上市后业绩连降两年